

This Page Is Inserted by IFW Operations
and is not a part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

IMAGES ARE BEST AVAILABLE COPY.

**As rescanning documents *will not* correct images,
please do not report the images to the
Image Problem Mailbox.**

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
20 June 2002 (20.06.2002)

PCT

(10) International Publication Number
WO 02/47662 A2

- (51) International Patent Classification⁷: A61K 9/08, 31/327
- (21) International Application Number: PCT/US01/48148
- (22) International Filing Date:
12 December 2001 (12.12.2001)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data:
09/734,748 12 December 2000 (12.12.2000) US
- (71) Applicant: IMAGINITIVE RESEARCH ASSOCIATES, INC. [US/US]; 116 Research Drive, Milford, CT 06460 (US).
- (72) Inventor: VISHNUPAD, Mohan; 155 Old Stonewall Road, Easton, CT 06612 (US).
- (74) Agents: DELUCA, Peter et al.; Dilworth & Barrese, 333 Earle Ovington Boulevard, Uniondale, NY 11553 (US).
- (81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, ZW.
- (84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— without international search report and to be republished upon receipt of that report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.



WO 02/47662 A2

(54) Title: ANTIBIOTIC/BENZOYL PEROXIDE DISPENSER

(57) Abstract: Two separate compositions, one containing an antibiotic and one containing benzoyl peroxide are packaged within and dispensed from a common dispenser. More particularly, a dual dispenser contains i) a first composition that is substantially anhydrous and includes a polar solvent, an antibiotic and a thickening agent selected from the group consisting of acrylic acid polymers and polyacrylamides; and ii) a second composition containing benzoyl peroxide or, alternatively, a retinoid. By packaging these two anti-acne active ingredients in this manner, long shelflife and convenient dispensing and application are provided.

ANTIBIOTIC/BENZOYL PEROXIDE DISPENSER**BACKGROUND****Technical Field**

This disclosure relates to compositions and apparatus for dispensing two distinct substances. More specifically, this disclosure relates to compositions and apparatus which allow long-term storage and subsequent dispensing of two compositions, to wit, a first composition
5 containing an antibiotic (such as erythromycin or clindamycin) and a second composition containing benzoyl peroxide or, alternatively, a retinoid.

Background of Related Art

Acne is a common inflammatory disease of human skin, and concentrates in skin areas where sebaceous glands are largest, most numerous, and most active. In its milder types, it is a
10 more or less superficial disorder which is evidenced by slight, spotty irritations and ordinary skin hygiene is a satisfactory treatment. However, in the more inflammatory types of acne, bacterial invasion of or about the pilosebaceous follicles occurs and pustules, infected cysts and, in extreme cases, canalizing inflamed and infected sacs appear. These lesions may become extensive and leave permanent, disfiguring scars.

15 Acne is very common by puberty and at least 80% of teenagers are afflicted. The facial eruptions are known to cause such psychic trauma in many adolescents that they find it difficult to make personal adjustments and consequently, withdraw and self-pity occur. The sufferer may be constantly aware of the obvious facial blemishes. For these reasons a medicinal preparation and treatment are of definite benefit and may eliminate the need for psychotherapy.

To reduce the severity of acne, various forms of medication have previously been topically applied to the skin. Antibacterial soaps have been used as well as bactericidal agents such as sulfur and resorcinol. Other topical compositions have separately contained benzoyl peroxide, hexachlorophene, erythromycin or neomycin sulfate. None of these prior preparations
5 has been completely effective.

As disclosed by Klein et al. (U.S. Pat. No. 4,497,794), it was discovered that a mixture on the skin of a peroxide, especially benzoyl peroxide and an antibiotic or antibacterial such as clindamycin, neomycin, sodium sulfacetamide, sulfur, tetracycline or erythromycin is particularly beneficial as they can exert a statistically significant synergistic effect. Peroxides inhibit the
10 formation of free fatty acids in the skin, primarily through inactivation of extracellular lipase (via oxidation) necessary to cleave triglycerides into free fatty acids and glycerol. The antibiotic or antibacterial component reduces the concentration of *Corynebacterium acnes* (i.e., *P. acnes*), a normal anaerobic bacteria which is the prime source of the lipase. Instead of the benzoyl peroxide, which is preferred, peroxides such as stabilized hydrogen peroxide and peroxides of
15 organic acids, such as a lauroyl peroxide, may be used.

As disclosed by Klein et al., erythromycin and benzoyl peroxide may be applied to the skin in combination in a preformulated aqueous-alcoholic gel. However, if a mixture is first made up and then applied to the skin, it is best that the mixture be made at the time of application or that the mixture be used within twenty-four hours. The prompt use of a premix is necessary
20 due to the chemical incompatibility of the two active agents. Because of this, it is advisable that the two agents be put in separate vials, bottles or other containers. For example, the Klein et al. patent discloses a kit containing, separately bottled liquid compositions comprising 5% benzoyl

peroxide and a solution of erythromycin in ethanol or acetone.

However, separately packaging multiple dosages of the two active ingredients presents a number of disadvantages to the end-user. For example, a unit application dosage of each active must be removed sequentially from each container and absorbed onto an applicator, such as a
5 cotton swab, so that it can be coated onto the skin of the user. This provides opportunities for spillage or over- or under-dosing, which can lead to skin irritation and other side effects. Furthermore, such a multidose system necessarily adds to the costs of packaging, shipping and storage.

A dispensing and applicator system intended to overcome these difficulties is disclosed in
10 U.S. Patent No. 5,562,642. A dual-pad package is disclosed therein that purportedly can contain, preserve and deliver single unit doses of two or more chemically- or physically-incompatible active ingredients. For example, an antibiotic in combination with a liquid, semi-liquid (cream) or gelled aqueous or non-aqueous vehicle can be absorbed by and retained by the first pad and a second ingredient which is physically- or chemically-incompatible with the antibiotic, such as a
15 peroxide, can be absorbed and retained by the second pad, preferably in combination with the appropriate vehicle.

It would be desirable to provide a means for simultaneously dispensing two active acne treating compounds in aesthetically acceptable vehicles which allow prolonged shelf life for both active compounds and easy mixing just prior to application to the skin.

SUMMARY

It has now been discovered that two separate compositions, one containing an antibiotic and one containing benzoyl peroxide can be packaged within and dispensed from a common dispenser. More particularly, a dual dispenser contains i) a first composition that is substantially anhydrous and includes a polar solvent, an antibiotic and a thickening agent selected from the group consisting of acrylic acid polymers and polyacrylamides; and ii) a second composition containing benzoyl peroxide. Preferably, the first and second compositions have viscosities that differ by no greater than 25%. By packaging these two anti-acne active ingredients in this manner, long shelflife and convenient dispensing and application are provided.

In an alternate embodiment, two separate compositions, one containing an antibiotic and one containing a retinoid are packaged within and dispensed from a common dispenser. More particularly, a dual dispenser contains i) a first composition that is substantially anhydrous and includes a polar solvent, an antibiotic and a thickening agent selected from the group consisting of acrylic acid polymers and polyacrylamides; and ii) a second composition that is substantially anhydrous, and includes a polar solvent, a retinoid, and a thickening agent selected from the group consisting of acrylic acid polymers and polyacrylamides.

Brief Description of the Drawings

Various embodiments are described herein with reference to the drawing wherein:

FIG. 1 is an schematic view of a container suitable for dispensing the first and second compositions in accordance with this disclosure.

Detailed Description of Preferred Embodiments

Antibiotic in a first, substantially anhydrous composition is dispensed simultaneously

with a second, benzoyl peroxide-containing composition in accordance with this disclosure.

By the term "substantially anhydrous" it is meant that, other than water of hydration contained in the various components used to formulate the composition, no free water is added to the composition. Typically, the water content of the composition will be less than 5% by weight. Preferably the water content of the composition is less than 3% and most preferably less than about 1% by weight of the composition.

The first composition is substantially anhydrous and contains a polar solvent, a thickening agent and an antibiotic. Preferably the antibiotic is one known to be useful in treating acne, such as, for example, erythromycin, tetracyclin, clindamycin, their derivatives or pharmaceutically acceptable salts. The antibiotic is preferably present in the first composition in an amount from about 0.001 wt. % to about 5 wt. %, more preferably about 0.1 wt. % to about 1.0 wt. %.

The first composition has a viscosity greater than about 1000 centipoise (cps) when measured using a Brookfield viscometer (model LVT) at room temperature using spindle number 3 or 4 at 0.3 to 30 rpm. It should be understood that all viscosities referred to herein are measured in this manner. Preferably, the first composition has a viscosity greater than 5,000 cps. In particularly useful embodiments, the first composition has a viscosity in the range of from about 1000 to about two million centipoise. Most preferably, the first composition has a viscosity in the range of about 10,000 cps to about 1,000,000 cps.

Polar solvents useful in the first composition include polyols. A polyol is a compound with at least two hydroxyl groups per molecule, i.e., a compound having multiple hydroxyl groups as part of its molecular structure. Among the useful polyols are polyhydric alcohols.

Propylene glycol, dipropylene glycol, polyethylene glycol and glycerine are particularly preferred polar solvents for use in the first composition.

The thickening agent used in the first composition is selected from the group consisting of acrylic acid polymers and polyacrylamides. The thickening agent are used in an amount
5 sufficient to obtain a composition of viscosity in the desired range.

Useful acrylic acid polymers include copolymers of (meth)acrylic acid and of monomers containing at least one fatty chain; these monomers are chosen from hydrophobic monomers with a fatty chain, amphiphilic monomers containing a hydrophobic part with a fatty chain and a hydrophilic part, or alternatively their mixtures. Suitable materials include, for example,
10 copolymers of C_{10-30} alkyl acrylates with one or more monomers of acrylic acid, methacrylic acid, or one of their short chain (i.e., C_{1-4} alcohol) esters, wherein the crosslinking agent is an allyl ether of sucrose or pentaerythritol. These copolymers are commonly referred to as acrylates/ C_{10-30} alkyl acrylate crosspolymers and are commercially available under the tradename CARBOPOL® from B.F. Goodrich, Cleveland, Ohio U.S.A. Other polymers useful in the
15 preparation of the present compositions are polymers of polyacrylic acid crosslinked with from about 0.75% to about 2.0% of polyalkyl sucrose or polyalkyl pentaerythritol often with molecular weights of 4 to 5 million or more that are commercially available, for example, under the trade designation CARBOPOL® 934, 940 and 941 from B.F. Goodrich, Cleveland, Ohio U.S.A. Anionic amphiphilic polymers which comprise 95% to 60% by weight of acrylic
20 recurring structural units, 4% to 40% by weight of acrylate recurring structural units and 0.1% to 6% by weight of crosslinking monomer, or (ii) which comprise 98% to 96% by weight of acrylic

recurring structural units, 1% to 4% by weight of acrylate recurring structural units and 0.1% to 0.6% by weight of crosslinking monomer are also useful as the thickening agent in the present compositions. Such polymers include, for example, those hydrophobically-modified cross-linked polymers of acrylic acid having amphipathic properties marketed by B.F. Goodrich under the trademarks CARBOPOL® 1342 and CARBOPOL® 1382. Also useful is ULTREZ® 10 (available from B. F. Goodrich), an oil in water emulsion of a modified acrylic copolymer comprising of a major portion of a monoolefinically unsaturated carboxylic acid monomer or its anhydride having a length of from about 3 to 6 carbon atoms and a minor portion of a C₈₋₃₀ chain acrylate or methacrylate ester monomer wherein the carboxylic acid or its anhydride is from about 80 to about 99% by weight and the C₈₋₃₀ chain acrylate or methacrylate ester monomer is from about 1% to about 20% by weight. The polymer is described in U.S. Pat. No. 5,004,598, hereby incorporated by reference in its entirety.

When used, these acrylic acid polymers are present in the first composition at a level from about 0.05% to about 20%, preferably from about 0.5% to 10% and most preferably from about 1% to about 10%.

The first composition can alternatively contain polyacrylamide polymers as the thickening agent, especially nonionic polyacrylamide polymers. The non-ionic polymers useful in the first composition are polyacrylamides and substituted polyacrylamides, branched or unbranched. These polymers are non-ionic polymers which can be formed from a variety of monomers including acrylamide and methacrylamide which are unsubstituted or substituted with one or two alkyl groups (preferably C₁₋₃). Preferred acrylate amides and methacrylate amides in

which the amide nitrogen is unsubstituted, or substituted with one or two C_{1-5} alkyl groups (preferably: methyl, ethyl or propyl), for example, acrylamide, methacrylamide, N-methylacrylamide, N-methylmethacrylamide, N,N-dimethylmethacrylamide, N-isopropylacrylamide, N-isopropylmethacrylamide and N,N-dimethylacrylamide. These monomers are generally disclosed in U.S. Pat. No. 4,963,348 which is incorporated by reference herein in its entirety. These copolymers may optionally be formed using conventional neutral crosslinking agents such as dialkenyl compounds. The use of such crosslinking agents for cationic polymers is disclosed in U.S. Pat. Nos. 4,628,078 and 4,599,379 both of which are incorporated by reference herein. These non-ionic copolymers may have a molecular weight greater than about 1,000,000 preferably greater than about 1,500,000 and range up to about 30,000,000. Most preferred among these polyacrylamide polymers is the nonionic polymer given the CTFA designation polyacrylamide and isoparaffin and laureth-7, available under the tradename SEPIGEL® 305 from Seppic Corporation (Fairfield, N.J.). Other polyacrylamide polymers useful herein include multi-block copolymers of acrylamides and substituted acrylamides with acrylic acids and substituted acrylic acids. Commercially available examples of these multi-block copolymers include Hypan SR150H, SS500V, SS500W, SSSA100H, from Lipo Chemicals, Inc., (Patterson, N.J.).

When used, these non-ionic polyacrylamides are present in the first composition at a level from about 0.05% to about 20%, preferably from about 0.5% to 10% and most preferably from about 1% to about 10%.

Quite surprisingly, it has been found that contrary to product literature relating to the commercially available acrylic acid polymers and polyacrylamides, when used in the first, substantially anhydrous composition, the thickening agents need not be dispersed in an aqueous medium or neutralized to provide the desired thickening.

5 The second composition contains benzoyl peroxide. The second composition can be any benzoyl peroxide-containing cream, lotion, gel or suspension. Examples of benzoyl peroxide compositions that are suitable for use in accordance with this disclosure include, but are not limited to the compositions disclosed in U.S. Patent No. 5,632,996, the disclosure of which is incorporated herein by reference. In particularly useful embodiments, the second composition is
10 also substantially anhydrous. Among these embodiments are compositions containing a) a polar solvent, b) a thickening agent selected from the group consisting of acrylic acid polymers, polyacrylamides and combinations thereof, c) benzoyl peroxide, d) alkyl benzoate and, optionally e) a synthetic cleanser. Suitable synthetic cleansers include, but are not limited to sodium cocoyl isethionate, alpha olefin sulfonate sarcosynates and acyl glutamates.

15 The amount of benzoyl peroxide in the second composition can be from about 0.1 to about 20 percent by weight based on the total weight of the second composition, preferably from about 1.0 to about 15 weight percent, most preferably from about 1.5 to about 10 weight percent.

 In an alternative embodiment, the second compositions is also substantially anhydrous and contains a polar solvent, a thickening agent and a retinoid. Suitable retinoids, include, for
20 example, retinol, retinoic acid, retinyl palmitate, retinyl propionate or retinyl acetate as well as synthetic retinoid mimics. The retinoid is preferably present in the second composition in an amount from about 0.001 wt. % to about 5 wt. %, more preferably about 0.1 wt. % to about 2.0

wt. %. Suitable polar solvents and thickening agents for the second composition are the same as described above for the first composition. In this alternative embodiment, the second, retinoid-containing composition can have a viscosity greater than about 1000 centipoise (cps) when measured using a Brookfield viscometer (model LVT) at room temperature using spindle number
5 3 or 4 at 0.3 to 30 rpm. Preferably, the second, retinoid-containing composition has a viscosity greater than 5,000 cps. In particularly useful embodiments, the second, retinoid-containing composition has a viscosity in the range of from about 1000 to about two million centipoise. Most preferably, the second, retinoid-containing composition has a viscosity in the range of about 10,000 cps to about 1,000,000 cps.

10 The first and second compositions preferably have viscosities that are similar to provide a cosmetically elegant product when the first and second compositions are simultaneously dispensed. In particularly useful embodiments the difference in viscosity between the first and second compositions is no more than about 25%.

In addition to the above-listed ingredients, one or both of the first and second
15 compositions may also contain a variety of non-essential ingredients such as, for example, co-solvents, preservatives, emollients, humectants, anti-inflammatory agents, antioxidants, insect repellents or skin cooling compounds, etc.

For example, either of the first or second composition may contain one or more co-solvents, such as ethanol, acetone or propylene carbonate.

20 A preservative can also be used in either or both of the first or second compositions. Preservatives suitable for use in connection with the present compositions include parabens, sorbates, benzyl alcohol, diazolidinyl urea and isothiazolinones. Preservatives can be present in

an amount from about 0.001 wt. % to about 15 wt. % of the total composition.

One or both of the first or second compositions can also be formulated to contain about 0.01 wt. % to about 30 wt. %, preferably about 1.0 wt. % to about 15 wt. % of the total composition, skin cooling compounds, such as menthol, methyl glycerol, asymmetrical carbonates, thiocarbonates and urethanes, substituted carboxamides, ureas or phosphine oxides as described in J. Cosmet. Chem., vol. 29, page 185 (1978) and incorporated herein by reference, methyl lactate and menthone glycerin acetal.

The first substantially anhydrous antibiotic compositions and the second benzoyl peroxide composition are stored in and dispensed from a multi-chamber dispenser. Dispensing systems suited for simultaneously dosing two separately contained incompatible compounds, are well known. As such, the dispensing system schematically depicted in FIG. 1 (dispenser from Maplast, Tradate, Italy) is just one example out of a number of products which range from small, two-chambered single use pouches to tubes using different product compartments or tubes compartmentalized using extrudable, viscous and relatively inert materials to separate the incompatible compounds.

The dispenser shown in FIG. 1 is able to simultaneously dose two compounds separately contained in A and B by pressing dosing head C. Pressing dosing head C activates two small pumps which subsequently dispense the two compounds in approximately equal volumes. Depending on the design of the dosing head, the compounds can be dosed in two separate streams or in just one stream.

If desired, a dispensing unit that is able to deliver The first and second substantially anhydrous compositions in a ratio, such as, for example, 1:2 can be used. Translated to the

dispenser depicted in FIG. 1, this would mean that one of the two pumps is able to dose at least twice the volume of the other pump in just one stroke of dosing head C. Translated to a two-chambered single use pouch, this would mean that the chamber containing the first substantially anhydrous composition contains at least half as much product volume as the other chamber.

5 Translated to a two-compartment tube, this would mean that under equal pressure the discharge orifice for the compartment containing the first substantially anhydrous composition allows the passage of at least twice as much product as the discharge orifice of the other compartment.

Translated to a tube which is compartmentalized using extrudable material, this would mean that first substantially anhydrous composition is present inside the tube in at least double the volume

10 of the second substantially anhydrous composition.

Other suitable dispensers are disclosed in U. S. Patent Nos. 5,356,040; 5,823,391, and 4,826,048 the disclosures of which are incorporated herein by this reference.

The following examples are presented to illustrate specific embodiments of the present compositions and methods. These examples should not be interpreted as limitations upon the

15 scope of the invention.

EXAMPLES I - IV

The following formulations are exemplary of substantially anhydrous antibiotic compositions suitable for use as the first composition:

	<u>I</u>	<u>II</u>	<u>III</u>
5 erythromycin	2	2	-
propylene glycol	96	71.5	96.0
ULTREZ 10	2	1.5	2.0
polyethylene glycol	-	25.0	-
clindamycin	-	-	1.0
10	<u>IV</u>		
erythromycin	2.0		
propylene glycol	96.0		
ULTREZ 10	1.0		
SEPIGEL 305	1.0		

15 EXAMPLES V - VI

The following exemplary benzoyl peroxide-containing formulations are suitable for use as the second composition to be dispensed simultaneously with any of the anhydrous formulations of Examples I-IV.

	<u>V</u>
20 Petrotalium	15.50
Sodium Cocoyl Isethionate	5.00
Alfa olefin Sulfonate	2.00
Titanium Dioxide	0.30
Lucidol 75% (Benzoyl Peroxide)	15.80
25 C ₁₂₋₁₅ Alkyl Benzoate	7.00
Triethanolamine	0.60
Carbopol 1382	0.80
Glycerin	58.0

VI - Gel Composition

	Water	56.4
	Glycerine	5.0
	SEPIGEL 305	2.0
5	Sodium Hydroxide	1.60
	Steareth S-20	2.0
	Steareth S-2	2.0
	Cetyl Stearyl Alcohol	3.0
	Silicone Copolydyl	5.0
10	Lucidol 75% (Benzoyl Peroxide)	16.0
	C ₁₂₋₁₅ Benzoate Ester	7.00

VII - Benzoyl Peroxide Gel

	propylene glycol	88.5
	ULTREZ 10	1.5
15	Benzoyl Peroxide	5.0
	Fin Solv TN	5.0

VIII - Benzoyl Peroxide Gel Cleanser

	glycerin	66.0
	ULTREZ 10	2.0
20	Benzoyl Peroxide	5.0
	Fin Solv TN	5.0
	Sodium Cocoyl Isethionate	20.0

It will be understood that various modifications may be made to the embodiments disclosed herein. Therefore, the above description should not be construed as limiting, but merely

25 as exemplifications of preferred embodiments. Those skilled in art will envision other modifications within the scope and spirit of the claims appended hereto.

WE CLAIM:

- 1 1. An apparatus comprising:
 - 2 a first chamber containing a first composition, the first composition being substantially
 - 3 anhydrous and comprising i) a polar solvent; ii) an antibiotic; and iii) a thickening agent in an
 - 4 amount sufficient to impart to the first composition a viscosity of at least 1000 centipoise
 - 5 measured at room temperature, the thickening agent being selected from the group consisting of
 - 6 acrylic acid polymers, polyacrylamides and combinations thereof;
 - 7 a second chamber containing a second composition comprising benzoyl peroxide; and
 - 8 one or more outlets for dispensing the first and second compositions.

- 1 2. An apparatus as in claim 1 wherein the first composition contains a thickening agent
 - 2 selected from the group consisting of copolymers of C_{10-30} alkyl acrylates with one or more
 - 3 monomers of acrylic acid, methacrylic acid, or one of their short chain (i.e., C_{1-4} alcohol) esters,
 - 4 crosslinked with an allyl ether of sucrose or pentaerythritol, polymers of polyacrylic acid
 - 5 crosslinked with from about 0.75% to about 2.0% of polyalkyl sucrose or polyalkyl
 - 6 pentaerythritol, anionic amphiphilic polymers which comprise 95% to 60% by weight of acrylic
 - 7 recurring structural units, 4% to 40% by weight of acrylate recurring structural units and 0.1% to
 - 8 6% by weight of a crosslinking monomer, polymers which comprise 98% to 96% by weight of
 - 9 acrylic recurring structural units, 1% to 4% by weight of acrylate recurring structural units and
 - 10 0.1% to 0.6% by weight of a crosslinking monomer, and copolymers of (meth)acrylic acid and of
 - 11 monomers containing at least one fatty chain, the monomers being selected from the group
 - 12 consisting of hydrophobic monomers with a fatty chain, amphiphilic monomers containing a

13 hydrophobic part with a fatty chain and a hydrophilic part and mixtures thereof.

1 3. An apparatus as in claim 1 wherein the first composition contains a thickening agent
2 selected from the group consisting of polyacrylamides and substituted polyacrylamides, branched
3 or unbranched.

1 4. An apparatus as in claim 1 wherein the first composition contains as the thickening agent
2 a mixture of polyacrylamide, C₁₃-C₁₄ isoparaffin and Laureth 7.

1 5. An apparatus as in claim 1 wherein the first composition contains a thickening agent at a
2 level from about 0.05% to about 20% by weight of the composition.

1 6. An apparatus as in claim 1 wherein the first composition contains a thickening agent at a
2 level from about 0.5% to about 10% by weight of the composition.

1 7. An apparatus as in claim 1 wherein the first composition contains a thickening agent at a
2 level from about 1% to about 10% by weight of the composition.

1 8. An apparatus as in claim 1 wherein the first composition contains a polar solvent selected
2 from the group consisting of polyols.

1 9. An apparatus as in claim 1 wherein the first composition contains a polar solvent

2 comprising one or more compounds selected from the group consisting of polyhydric alcohols.

1 10. An apparatus as in claim 1 wherein the first composition contains a polar solvent
2 comprising one or more compounds selected from the group consisting of propylene glycol,
3 dipropylene glycol, polyethylene glycol and glycerine.

1 11. An apparatus as in claim 1 wherein the first composition contains an antibiotic selected
2 from the group consisting of erythromycin, clindamycin, tetracycline, their derivatives and
3 pharmaceutically acceptable salts.

1 12. An apparatus as in claim 1 wherein benzoyl peroxide comprises from about 0.1 to about
2 25 weight percent of the second composition.

1 13. An apparatus as in claim 1 wherein the second composition is substantially anhydrous.

1 14. An apparatus as in claim 1 wherein the second composition comprises (i) a polar solvent;
2 (ii) a thickening agent selected from the group consisting of acrylic acid polymers,
3 polyacrylamides and combinations thereof; (iii) benzoyl peroxide; (iv) alkyl benzoate; and
4 optionally (v) a synthetic cleanser.

1 15. A method of treating acne comprising
2 simultaneously dispensing a first composition and a second composition, the first

3 composition being substantially anhydrous and comprising i) a polar solvent; ii) an antibiotic;
4 and iii) a thickening agent in an amount sufficient to impart to the first substantially anhydrous
5 composition a viscosity of at least 1000 centipoise measured at room temperature, the
6 thickening agent being selected from the group consisting of acrylic acid polymers,
7 polyacrylamides and combinations thereof, the second composition comprising benzoyl
8 peroxide; and
9 contacting the first composition and second composition with the skin of a person
10 afflicted with acne.

1 16. A method as in claim 15 wherein the first composition contains an antibiotic selected
2 from the group consisting of erythromycin, clindamycin, tetracycline, and their derivatives and
3 pharmaceutically acceptable salts.

1 17. A method as in claim 15 wherein the second composition is substantially anhydrous.

1 18. A method as in claim 15 wherein the second composition comprises (i) a polar solvent;
2 (ii) a thickening agent selected from the group consisting of acrylic acid polymers,
3 polyacrylamides and combinations thereof; (iii) benzoyl peroxide; (iv) alkyl benzoate; and
4 optionally (v) a synthetic cleanser.

1 19. An apparatus comprising:
2 a first chamber containing a first composition, the first composition being substantially

3 anhydrous and comprising i) a polar solvent; ii) an antibiotic; and iii) a thickening agent in an
4 amount sufficient to impart to the first composition a viscosity of at least 1000 centipoise
5 measured at room temperature, the thickening agent being selected from the group consisting of
6 acrylic acid polymers, polyacrylamides and combinations thereof;
7 a second chamber containing a second composition the second composition comprising i)
8 a polar solvent; ii) a retinoid; and iii) a thickening agent in an amount sufficient to impart to the
9 second composition a viscosity of at least 1000 centipoise measured at room temperature, the
10 thickening agent being selected from the group consisting of acrylic acid polymers,
11 polyacrylamides and combinations thereof; and
12 one or more outlets for dispensing the first and second compositions.

1 20. An apparatus as in claim 19 wherein the first composition contains an antibiotic selected
2 from the group consisting of erythromycin, clindamycin, tetracycline, their derivatives and
3 pharmaceutically acceptable salts.

1 21. An apparatus as in claim 19 wherein the second composition comprises a retinoid
2 selected from the group consisting of retinol, retinoic acid, retinyl palmitate, retinyl propionate,
3 retinyl acetate and synthetic retinoid mimetics.

1 22. A method of treating acne comprising
2 simultaneously dispensing a first composition and a second composition, the first
3 composition being substantially anhydrous and comprising i) a polar solvent; ii) an antibiotic;

4 and iii) a thickening agent in an amount sufficient to impart to the first substantially anhydrous
5 composition a viscosity of at least 1000 centipoise measured at room temperature, the
6 thickening agent being selected from the group consisting of acrylic acid polymers,
7 polyacrylamides and combinations thereof, the second composition being substantially
8 anhydrous and comprising i) a polar solvent; ii) a retinoid; and iii) a thickening agent in an
9 amount sufficient to impart to the second composition a viscosity of at least 1000 centipoise
10 measured at room temperature, the thickening agent being selected from the group consisting of
11 acrylic acid polymers, polyacrylamides and combinations thereof; and
12 contacting the first composition and second composition with the skin of a person
13 afflicted with acne.

1 23. A method as in claim 22 wherein the first composition contains an antibiotic selected
2 from the group consisting of erythromycin, clindamycin, tetracycline, and their derivatives and
3 pharmaceutically acceptable salts.

1 24. A method as in claim 22 wherein the second composition comprises a retinoid selected
2 from the group consisting of retinol, retinoic acid, retinyl palmitate, retinyl propionate, retinyl
3 acetate, and synthetic retinoid mimetics.

1/1




FIG. 1

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
20 June 2002 (20.06.2002)

PCT

(10) International Publication Number
WO 02/047662 A3

- (51) International Patent Classification⁷: A61K 9/08, 31/327
- (21) International Application Number: PCT/US01/48148
- (22) International Filing Date:
12 December 2001 (12.12.2001)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data:
09/734,748 12 December 2000 (12.12.2000) US
- (71) Applicant: IMAGINITIVE RESEARCH ASSOCIATES, INC. [US/US]; 116 Research Drive, Milford, CT 06460 (US).
- (72) Inventor: VISHNUPAD, Mohan; 155 Old Stonewall Road, Easton, CT 06612 (US).
- (74) Agents: DELUCA, Peter et al.; Dilworth & Barrese, 333 Earle Ovington Boulevard, Uniondale, NY 11553 (US).
- (81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, ZW.
- (84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
- Published:
— with international search report
- (88) Date of publication of the international search report:
13 March 2003
- For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.*



WO 02/047662 A3

(54) Title: ANTIBIOTIC/BENZOYL PEROXIDE DISPENSER

(57) Abstract: Two separate compositions, one containing an antibiotic and one containing benzoyl peroxide are packaged within and dispensed from a common dispenser. More particularly, a dual dispenser contains i) a first composition that is substantially anhydrous and includes a polar solvent, an antibiotic and a thickening agent selected from the group consisting of acrylic acid polymers and polyacrylamides; and ii) a second composition containing benzoyl peroxide or, alternatively, a retinoid. By packaging these two anti-acne active ingredients in this manner, long shelflife and convenient dispensing and application are provided.

INTERNATIONAL SEARCH REPORT

 International Application No
 PCT/US 01/48148

 A. CLASSIFICATION OF SUBJECT MATTER
 IPC 7 A61K9/08 A61K31/327

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

 Minimum documentation searched (classification system followed by classification symbols)
 IPC 7 A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

WPI Data, PAJ, CHEM ABS Data

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 99 02133 A (GIST-BROCADES) 21 January 1999 (1999-01-21) claims examples page 3, line 17 - line 24 page 3, line 29 - page 4, line 1 page 4, line 17 - line 27 page 7, line 10 - line 18	1-24
X	CA 2 015 111 A (T.J.WOO) 23 October 1991 (1991-10-23) claims --- -/-	1, 11, 15, 16, 19-24

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents:

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

T later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

X document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

Y document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

Z document member of the same patent family

Date of the actual completion of the international search

11 October 2002

Date of mailing of the international search report

18/10/2002

Name and mailing address of the ISA

 European Patent Office, P.B. 5818 Patentlaan 2
 NL - 2280 HV Rijswijk
 Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
 Fax (+31-70) 340-3016

Authorized officer

Scarponi, U

INTERNATIONAL SEARCH REPORT

International Application No
PCT/US 01/48148

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X,P	WO 01 91726 A (DERMIK) 6 December 2001 (2001-12-06) claims figures 4,5 page 25, line 22 - line 25 page 27, line 25 - line 28 page 29, line 11 -page 30, line 7 page 31, line 5 - line 13 examples	1-24
A	US 4 497 794 A (R.W.KLEIN ET AL.) 5 February 1985 (1985-02-05) cited in the application claims examples 3-10 figure 1	1-24
A	US 5 562 642 A (J.A.SMITH ET AL.) 8 October 1996 (1996-10-08) cited in the application claims 1-17 figures	1-24
A	EP 0 960 618 A (L.J.BAROODY ET AL.) 1 December 1999 (1999-12-01) claims figures	1-24

INTERNATIONAL SEARCH REPORT

national application No.
PCT/US 01/48148

Box I Observations where certain claims were found unsearchable (Continuation of Item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:

Although claims 15-18, 22-24 are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.
2. ☐ Claims Nos.:
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this International application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

 International Application No
 PCT/US 01/48148

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
WO 9902133	A	21-01-1999	AU 9259598 A BR 9810985 A CN 1262616 T WO 9902133 A2 EP 0996428 A2 JP 2001509477 T US 6448233 B1	08-02-1999 15-08-2000 09-08-2000 21-01-1999 03-05-2000 24-07-2001 10-09-2002
CA 2015111	A	23-10-1991	CA 2015111 A1	23-10-1991
WO 0191726	A	06-12-2001	AU 7520101 A WO 0191726 A1	11-12-2001 06-12-2001
US 4497794	A	05-02-1985	MX 9203750 A1 AR 229405 A1 AT 381452 B AT 285581 A AU 557147 B2 AU 7202981 A BE 889327 A1 CA 1179599 A1 CH 656307 A5 CH 647147 A5 DE 3124698 A1 DK 273981 A ES 503797 D0 ES 8303087 A1 FR 2495471 A1 GB 2090135 A GB 2088717 A , B IE 52227 B1 IT 1210608 B JP 57099525 A MX 6555 E NL 8102997 A NZ 197491 A NZ 209389 A PH 19245 A SE 8103925 A US 4692329 A ZA 8104215 A	01-09-1992 15-08-1983 27-10-1986 15-03-1986 11-12-1986 17-06-1982 16-10-1981 18-12-1984 30-06-1986 15-01-1985 08-07-1982 09-09-1982 01-03-1983 01-05-1983 11-06-1982 07-07-1982 16-06-1982 19-08-1987 14-09-1989 21-06-1982 10-07-1985 01-07-1982 28-02-1985 28-02-1985 14-02-1986 09-06-1982 08-09-1987 23-02-1983
US 5562642	A	08-10-1996	US 5417674 A US 5254109 A WO 9413353 A1	23-05-1995 19-10-1993 23-06-1994
EP 960618	A	01-12-1999	EP 0960618 A2 AT 197248 T AU 3478893 A BR 9305884 A CA 2130341 A1 CN 1077887 A , B DE 69329617 D1 DE 69329617 T2 DK 626844 T3 EP 0626844 A1 ES 2153377 T3 FI 943783 A	01-12-1999 15-11-2000 03-09-1993 19-08-1997 19-08-1993 03-11-1993 07-12-2000 23-05-2001 22-01-2001 07-12-1994 01-03-2001 17-08-1994

INTERNATIONAL SEARCH REPORT

International Application No
PCT/US 01/48148

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
EP 960618	A	JP 7504168 T	11-05-1995
		MX 9300848 A1	31-08-1994
		NO 943045 A	17-08-1994
		NZ 249021 A	27-08-1996
		PL 171127 B1	28-03-1997
		PT 626844 T	30-03-2001
		RU 2122412 C1	27-11-1998
		SG 48195 A1	17-04-1998
		WO 9315726 A1	19-08-1993
		US 5733886 A	31-03-1998
		US 6117843 A	12-09-2000